Y mAbs Therapeutics

Y mAbs Therapeutics — Corporate Update (January 2024)

25 slides from Y mAbs Therapeutics's corporate update, Jan 9, 2024

  1. Slide 1: Oncology Leadership in Pretargeted Radioimmunotherapy Platform and Antibody-based Therapies

    Oncology Leadership in Pretargeted Radioimmunotherapy Platform and Antibody - based Therapies January 2024

  2. Slide 2: Disclaimer

    Disclaimer Statements in this presentation about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, constitute “forward - looking statements” within the meaning of Section 27 A of the Securities Act of 1933 and Section 21 E of t

  3. Slide 3: Strongly Positioned to Drive Future Value

    Strongly Positioned to Drive Future Value 3 Novel Platforms in Development S elf - A ssembly D is A ssembly (“SADA”) Pretargeted Radioimmunotherapy Platform (“PRIT ”) Monoclonal Antibodies GD2 - SADA Phase I Part A Data Readout CD38 - SADA Phase I Study Initiation MSK Data Readout of Phase II Osteos

  4. Slide 4: Advancing Focused Pipeline with Multiple Value-Added Catalysts Ahead

    Advancing Focused Pipeline with Multiple Value - Added Catalysts Ahead 4 Study Therapeutic Area Preclinical Phase I Phase II/Pivotal Approved Trial Sponsor Status Lead Programs 201 Relapsed/Refractory High - Risk Neuroblastoma (Pediatric) U.S. FDA approved Naxitamab - gqgk (Anti - GD2) 12 - 230 Rela

  5. Slide 5: Novel SADA Pretargeted Radioimmunotherapy Technology Platform

    5 Novel SADA Pretargeted Radioimmunotherapy Technology Platform

  6. Slide 6: Current Radiopharma Challenges Negatively Impact Patient Care

    Current Radiopharma Challenges Negatively Impact Patient Care 6 Infrastructure and Manufacturing Physician Participation Administration Sites Continuing Drug Shortages Simpler, more user - friendly solutions greatly needed for physicians and patients

  7. Slide 7: SADA's Novel Pretargeted-Step Approach a Potential Industry Game-Changer

    SADA’s Novel Pretargeted 2 - Step Approach a Potential Industry Game - Changer * 7 Novel SADA Platform Potential Capabilities x Pretargeting tumor potentially minimizes toxicity and potentially enhances rapid clearing of unbound protein x Potential to work with short T 1/2 isotopes x Potentially bro

  8. Slide 8: Self-Assembly Disassembly (SADA) Technology

    S elf - A ssembly D is A ssembly (SADA) Technology: High Affinity for Tumor Targets and Rapid Clearance from Blood Stream SADA domains uniquely selected to allow proteins to change size based on concentration Adapted from Santich et al. Clin Canc Res 2020 S elf - A ssembled Tetramer ~200 kDa Strong

  9. Slide 9: Conventional GD2 Antibody's Persistence in Blood Stream Leads to Unwanted Exposure

    Conventional GD2 Antibody’s Persistence in Blood Stream Leads to Substantial Unwanted Exposure and Increased Toxicity 9 Adapted from Santich et al. Clin Canc Res 2021 Blood E xposure (Radioactive P ayload ) 1. IgG Bispecific 2. DOTA Time Concentration (Radioactive Payload) Tumor

  10. Slide 10: GD2-SADA Achieves High Tumor Uptake with Minimal Exposure to Other Tissues

    GD2 - SADA Achieves High Tumor Uptake with Minimal Exposure to All Other Tissues 10 Blood E xposure (Radioactive Payload) 1. IgG Bispecific 2. DOTA 1. SADA Bispecific 2. DOTA Concentration (Radioactive Payload) Tumor Tumor U ptake (Radioactive P ayload ) Adapted from Santich et al. Clin Canc Res 202

  11. Slide 11: Study 1001: GD2-SADA Ongoing Phase I Clinical Trial

    Part A N = 15 - 18 › GD2 – SADA protein dose escalation from 0.3 mg/kg to 10 mg/kg with fixed therapeutic 177 Lu - DOTA dose of 200 mCi (7.4 GBq) – interval between SADA and payload to be explored Part B N = 9 - 12 › 177 Lu - DOTA therapeutic dose escalation from 400 mCi (14.8 GBq) to 750 mCi (27.8

  12. Slide 12: Study 1001: SPECT/CT Scan Demonstrating Tumor Binding of Lu-GD2 SADA

    Study 1001: SPECT/CT Scan Demonstrating Tumor Binding of 177 Lu - GD2 SADA * • Example of tumor targeting in Osteosarcoma using 177 Lu - DOTA dose of 30 mCi (imaging dose) in patient • Arrow indicates tumor metastasis located in the Thoracic cavity – with 177 Lu - DOTA uptake • Scan performed 24 hou

  13. Slide 13: Study 1001: SPECT/CT Scan on Osteosarcoma Patient Demonstrating Positive Tumor Uptake

    Study 1001: SPECT/CT Scan on Osteosarcoma Patient Demonstrating Positive Tumor Uptake After Exposure * • Patient treated with 0.3 mg/kg GD2 - SADA, followed by 200 mCi 177 Lu - DOTA (lowest therapeutic radionuclide dose) 48 - hours later • Scan performed 24 hours after radionuclide administration •

  14. Slide 14: Ongoing GD2-SADA Phase I Trial: Initial PK Data

    Ongoing GD2 - SADA Phase I Trial: Initial PK Data * 14 Non - QC data 0 20 40 60 80 100 120 140 GD2 - SADA conc Hours *These early results are not complete and are not necessarily indicative of the full results or ultimate success of the SADA tri als or the SADA development program. Limitation: Patie

  15. Slide 15: Novel SADA Platform Potentially Provides Simplicity and Enhanced Precision

    15 Novel SADA Platform Potentially Provides Simplicity and Enhanced Precision for Physicians and Patients * › Additional early - stage programs include: › HER2 - SADA › B7H3 - SADA Ongoing GD2 - SADA Phase I Trial (Study 1001) › Evidence of tumor update › No DLTs or pain observed to date › Demonstra

  16. Slide 16: Planned CD38-SADA Phase I Clinical Trial (Study 1201): Study Design

    Part A N = 12 - 15 › CD38 - SADA dose escalation with fixed imaging and therapeutic 177 Lu - DOTA doses Part B N = 12 - 15 › 177 Lu - DOTA therapeutic dose escalation with the CD38 - SADA dose determined in Part A Part C N = 20 › Repeated dosing up to 6 cycles Planned CD38 - SADA Phase I Clinical Tr

  17. Slide 17: Commercial Progress DANYELZA: GD2 Antibody for R/R High-Risk Neuroblastoma

    17 Commercial Progress DANYELZA® ( naxitamab - gqgk ): GD2 Antibody for R/R High - Risk Neuroblastoma

  18. Slide 18: Solid Drivers of Market Uptake

    Solid Drivers of Market Uptake • New DANYELZA campaign rolled out in Q4 2023 • 167 new patient starts to date since 2021 launch • Increasing share of U.S. anti - GD2 market with 17% ** DANYELZA: Only FDA - Approved Medicine for R/R NB Patients 18 Neuroblastoma • NB forms in certain types of nerve ti

  19. Slide 19: Prespecified Interim Analysis: Waterfall Plot of Change in Curie Score

    Study 201 Prespecified Interim Analysis: Waterfall Plot of Change in Curie Score in all Relapsed/Refractory Patients with Bone Disease (n = 48) Adapted from: Kushner B, et al. Poster presented at ESMO - IO; Geneva, Switzerland; December 6 - 8, 2023 19

  20. Slide 20: Ongoing Naxitamab Clinical Trials

    Ongoing Naxitamab Clinical Trials • Phase II BCC multi - center trial evaluating naxitamab + standard induction therapy in patients with newly diagnosed High - Risk Neuroblastoma • 13 sites initiated; target 40 - 50 sites in U.S. and Canada • 6 patients dosed; target 76 total patients • Multi - cent

  21. Slide 21: Ongoing and Potential New Studies for Naxitamab: Expanding Usage in New Indications

    Ongoing and Potential New Studies for Naxitamab : Expanding Usage in New Indications Cancer Indications T reatable Patient Population (U.S.) GD2 E xpression High - Risk Neuroblastoma Relapsed / Refractory 300 ~ 99 - 100% Front - line Induction 450 Osteosarcoma Relapsed/ R ecurrent 200 ~ 88% Soft - T

  22. Slide 22: DANYELZA Addresses Significant Unmet Needs in R/R High-Risk NB

    22 DANYELZA Addresses Significant Unmet Needs in R/R High - Risk NB with Expansion Potential Across Broader Patient Populations U.S. commercialization in high - risk NB. Launch in China by SciClone; LATAM partner Adium ; EU access via WEP Studies 12 - 230 and 201 formed primary basis of approval in

  23. Slide 23: Company Takeaways

    NZ -mAbs Ng Therapeutics, Inc. Company Takeaways

  24. Slide 24: Strongly Positioned to Drive Future Value

    Strongly Positioned to Drive Future Value 24 Novel Platforms in Development S elf - A ssembly D is A ssembly (“SADA”) Pretargeted Radioimmunotherapy Platform (“PRIT ”) Monoclonal Antibodies GD2 - SADA Phase I Part A Data Readout CD38 - SADA Phase I Study Initiation MSK Data Readout of Phase II Osteo

  25. Slide 25: Thank You

    THANK YOU

Y-mAbs Therapeutics — Corporate Update (January 2024) on 6ix